Zacks Investment Research upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a research note released on Friday, November 10th. Zacks Investment Research currently has $5.25 price target on the biotechnology company’s stock.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
A number of other equities analysts have also weighed in on ZIOP. ValuEngine lowered shares of ZIOPHARM Oncology from a hold rating to a sell rating in a research report on Monday, August 14th. BidaskClub upgraded shares of ZIOPHARM Oncology from a sell rating to a hold rating in a research report on Tuesday, August 8th. Finally, HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the stock a buy rating in a research report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $12.58.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) earnings per share. sell-side analysts predict that ZIOPHARM Oncology will post -0.54 EPS for the current fiscal year.
In related news, CEO Laurence James Neil Cooper bought 6,440 shares of the stock in a transaction dated Wednesday, November 8th. The shares were purchased at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 10.40% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in ZIOPHARM Oncology by 7.6% during the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock valued at $48,917,000 after purchasing an additional 553,933 shares in the last quarter. State Street Corp raised its stake in ZIOPHARM Oncology by 12.8% during the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after purchasing an additional 517,057 shares in the last quarter. Morgan Stanley raised its stake in ZIOPHARM Oncology by 19.5% during the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after purchasing an additional 324,774 shares in the last quarter. Northern Trust Corp raised its stake in shares of ZIOPHARM Oncology by 10.1% in the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock valued at $10,144,000 after acquiring an additional 149,067 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of ZIOPHARM Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock valued at $6,444,000 after acquiring an additional 38,173 shares during the period. 40.23% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “ZIOPHARM Oncology (ZIOP) Rating Increased to Buy at Zacks Investment Research” was originally posted by BBNS and is owned by of BBNS. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://baseballnewssource.com/markets/ziopharm-oncology-inc-ziop-upgraded-at-zacks-investment-research/1774956.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with our FREE daily email newsletter.